Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms

• Status: Completed
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: Male

Summary

This is an open-label extension study of another study protocol, MCS-2-TWN-a. Subjects who have completed the 12-week treatment and procedures under the protocol MCS-2-TWN-a will be eligible for this study.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Health Ever Bio-Tech Co., Ltd.

Criteria

Inclusion Criteria:

• Subject has completed 12 weeks of treatment under the protocol MCS-2-TWN-a.

• Subject is able to understand and willing to conform to the study procedures and has signed the informed consent form for participation in this extension study.

Exclusion Criteria:

• Subject has severe LUTS at the last visit under the protocol MCS-2-TWN-a.

• Subject is considered ineligible for the study by the investigator(s).